Navigation Links
Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer

of all the results reported. In comparison, the chance of living five years was 5.4% among patients treated with Eloxatin(R) plus irinotecan (IROX) (p=.016) and 3.8% (p<.001) among patients treated with the combination of 5-FU/LV and irinotecan (IFL).

FOLFOX4 slowed the progression of the disease compared to IROX and IFL. The median TTP was significantly longer among FOLFOX4-treated patients at 9.2 months compared to 6.5 months with IROX (p=<.001) and 6 months with IFL (p=<.001). FOLFOX4 patients were significantly more likely to experience any grade 3 or greater side effects (odds ratio of 1.65, p<.001) and were lower in men than in women (OR 0.63, p<0.001). The most common side effects were peripheral sensory neuropathy, fatigue, neutropenia, nausea, vomiting, and diarrhea.

"Our five-year overall survival results with first-line FOLFOX4 set a new benchmark for treating metastatic colorectal cancer," said lead investigator Richard Goldberg, MD, University of North Carolina School of Medicine, Chapel Hill, NC. "Adding Eloxatin(R) to standard chemotherapy significantly prolonged survival for these patients and also delayed disease progression."

Treatment with FOLFOX4 Predicts Important Benefits

Receiving FOLFOX4 was found to be the most powerful prognostic factor for predicting overall survival as well as time to progression. Those factors that were predictive of a worse outcome were: higher baseline performance status, neutrophil count, and alkaline phosphatase, as well as a greater number of disease sites. While being 70 years or older was associated with poorer survival, it was not predictive of time to progression, response rate or grade 3 or greater toxicity.

For more information about Eloxatin(R) or for full prescribing information, including BOXED WARNING, visit www.eloxatin.com.

About Colorectal Cancer

Strides have been made in the management of colorectal
'"/>




Page: 1 2 3 4

Related medicine technology :

1. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
2. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
3. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
4. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
5. Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients
6. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
7. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
8. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
9. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
10. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
11. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
Post Your Comments:
(Date:8/18/2008)...- Oramed,Pharmaceuticals, I...developer,of oral delivery systems, announced toda... Assess the Safety, Pharmacokinetics (PK) and,Phar...s in Healthy,Subjects," has been chosen for presen...European Association for the Study of Diabetes (EA...
(Date:8/17/2008)...nhua-- Pharmaxis,(ASX: PXS;...tal Phase 3,clinical trial of Bronchitol for the t...t., The first efficacy data from the trial is exp...9. The trial commenced its dosing phase in,April 2... subjects in June,2008 and closed today with 325 s...
(Date:8/14/2008)...BiTE) showing clinical benefit in cancer,patients;...gnize and attack canc...tCall/ -- Micromet, Inc.,(Nasdaq: MITI ), a bioph...,antibodies for the treatment of cancer, inflammat...cation of a Phase 1 clinical study(1) on its,BiTE(...
(Date:8/13/2008)...irstCall/ -- As biotechnology,pharmaceutical and ...l,trials beyond their own borders to other parts o...h America, complicated regulatory environments,cha...ing to an analysis by,Aon Corporation (NYSE: AOC ...ose companies a visual representation of the compl...
Breaking Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4Healthcare M 26A Activity on the Rise 9649 1Healthcare M 26A Activity on the Rise 9649 2Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 1Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 2Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 3New Poll 3A Only 16 25 of Californians Support Mandatory Purchase of Private Health Insurance 3B 71 25 Behind Regulation of Premium Increases 9641 1New Poll 3A Only 16 25 of Californians Support Mandatory Purchase of Private Health Insurance 3B 71 25 Behind Regulation of Premium Increases 9641 2Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 1Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 2
...ch 12, 2007: Progen Industries Limited,(ASX: PGL; ...8,Phase II liver cancer data has been accepted for...ssociation for the Study of the Liver,(EASL). Prog...er,cancer trial at the American Association for Ca...xpectation of having final data fully analysed and...
...d Safety Profile and Excellent,Pharmacokinetic Pro... 2007 /PRNewswire/ --,CeNeRx BioPharma, Inc., a cl...g innovative treatments for diseases of the centra... from a Phase I,clinical trial of Tyrima(TM), its ... anxiety. In this study, Tyrima was safe and well,...
Other Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
(Date:8/20/2008)...usetts General Hospital (MGH) investigators have f...em cell appeared to protect gastrointestinal tissu...ir report published in the journal Stem Cells , t...icine report that mesenchymal stem cells (MSCs), k...allowed the regeneration of the gastrointestinal l...
(Date:8/20/2008)...NGTON, Aug. 20 /PRNewswire-USNewswire/ -- Yesterda... admitted to Huron Hospital after,suffering an ane...Ohio. At,the present time Rep. Tubbs Jones, condit...are available., Tuesday,s condition followed a fu...ming forum on electoral reform, scheduled for Sept...
(Date:8/20/2008)... Micro(R) PUMP and ELLEgirl.com Send Four Girls to...Summer, LOS ANGELES, Aug. 20 /PRNewswire/ -- Reti...eenage Web site ELLEgirl.com to send four contest,...Camp in Santa Monica,California. With the new sch...mpower girls to become successful women by helping...
(Date:8/20/2008)...IEGO, Aug. 20 /PRNewswire/ --You,re late for work,...r car won,t start. How do you deal with,the rising...ash out in,frustration, how you deal with anger af...r children and even your career., As hard as we m...push,our buttons. While feeling anger isn,t a bad ...
Breaking Medicine News(10 mins):Health News:Bone marrow stem cells may help control inflammatory bowel disease 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 2Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 4Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 5Health News:Taming Your Temper: Learning to Turn Down the Heat 2
...oLipo(TM) laser module received clearance from the...ted lipolysis, and its BBL(TM) broadband pulsed li...les. ProLipo represents the latest technological ...ber-delivered laser energy to target fatty tissue....
... food for its 2.3 million soldiers, with the milit... recent spate of health scandals, state media rep...e or substandard food products and eliminating the... eating from the same plate, according to an annou...
...r a day, the Australian police finally announced t... in southern India, was being charged with provid...em a mobile phone SIM card. His cousin Sabeel Ahm... in Runcorn, southeast of Liverpool, has been accu...
... registry of pregnancies and abortions to stem sel... according to a report. India has only 927 femal...ldwide average of 1,050 females -- mainly due to s...e country where many people prefer to have male ch...
Other Medicine News:Health News:Sciton Receives FDA Clearance for Lipolysis and Wrinkle Treatment 2Health News:Three Doctors Charged So Far in the UK Bombing Case 2Health News:Three Doctors Charged So Far in the UK Bombing Case 3Health News:Three Doctors Charged So Far in the UK Bombing Case 4Health News:India to Monitor Pregnancies to Check Girl Foeticide: Report 2
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
Medicine Products: